Short-cycle dosing of three-drug HIV regimen not a viable strategy for teens
15 Jul 2026
byJairia Dela Cruz
In adolescents living with HIV, a 5-days-on and 2-days-off dosing of antiretroviral therapy (ART) with tenofovir disoproxil fumarate, lamivudine, and dolutegravir fails to match the efficacy of continuous dosing for maintaining viral suppression, as shown in the BREATHER Plus trial conducted in Africa.